ALBERTDAVD.NS Stock Analysis
AL
Avoid
Based on Eyestock quantitative analysis, ALBERTDAVD.NS`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
High score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly overvalued
Market cap $B
0.035
Dividend yield
1.59 %
Shares outstanding
5.707 B
Albert David Ltd. engages in the manufacturing and trade of pharmaceuticals. The company is headquartered in Kolkata, West Bengal and currently employs 1,271 full-time employees. The company went IPO on 2016-06-14. The firm offers its products under various categories, which includes parenteral, oral/enteral, topical agents and vision care. Its parenteral consists of amino acids infusion, antimicrobial, anti-leishmaniasis (kalazar), hemostat, neurotropic vitamin, and placenta extract. Its oral/enteral consists of amino acids oral, anthelmintic, anti-microbial, anti ulcerants, anti-vertigo, appetite stimulants, anti-tubercular, hematinic, oral vitamin b complex and expectorant / cough syrup. Its topical agents consist of non-steroidal anti-inflammatory drugs (NSAID). Its vision care consists of anti-glaucoma, anti-infective, tear substitutes and anti-infective with NSAID. The company has presence in Southeast Asia, Africa, countries of Middle - East, Europe, United States of America, and Latin America.